Literature DB >> 11358848

Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation.

V Ellenrieder1, S F Hendler, W Boeck, T Seufferlein, A Menke, C Ruhland, G Adler, T M Gress.   

Abstract

The aim of this study was to examine the effects of transforming growth factor (TGF) beta1 on the phenotype and the biological behavior of pancreatic cancer cell lines with and without mutations in the TGF-beta signaling pathway and to elucidate whether the Ras signaling cascade participates in mediating these effects of TGF-beta1. TGF-beta-responsive (PANC-1, COLO-357, and IMIM-PC1) and nonresponsive (CAPAN1 and IMIM-PC2) pancreatic cancer cell lines with activating mutations of the Ki-Ras oncogene were treated with 10 ng/ml TGF-beta1 over time. Phenotypic alterations were studied by electron and phase contrast microscopy and by immunohistochemistry and expression analyses of differentiation markers. The influence of TGF-beta on tumor cell scattering, migration, and invasion was determined. The role of the Ras-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) cascade in mediating TGF-beta-induced morphological and functional effects were studied by pretreatment with the MEK1 inhibitor PD 98059 and by measuring ERK2 activation using immune complex kinase assays. TGF-beta1 led to a reversible and time-dependent epithelial-mesenchymal transdifferentiation (EMT) in TGF-beta-responsive pancreatic cancer cell lines, characterized by a fibroblastoid morphology and an up-regulation of mesenchymal markers and a down-regulation of epithelial markers. EMT was associated with an increase in tumor cell migration, invasion, and scattering. In the responsive cell lines, TGF-beta1 induced a moderate but sustained activation of ERK2. EMT, the concomitant changes in gene expression, and the invasive and migratory potential were reduced or abolished by pretreatment with the selective MEK1 inhibitor. Thus, in TGF-beta-responsive pancreatic cancer cells with activating Ki-Ras mutations, TGF-beta1 treatment caused an EMT associated with a more invasive phenotype. Cross-talk with the Ras-MEK-ERK-signaling cascade appears to be essential for mediating these effects of TGF-beta1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358848

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  129 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway.

Authors:  Jin H Li; Wansheng Wang; Xiao R Huang; Matthew Oldfield; Ann M Schmidt; Mark E Cooper; Hui Y Lan
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

3.  Erbin inhibits TGF-β1-induced EMT in renal tubular epithelial cells through an ERK-dependent pathway.

Authors:  Qiaodan Zhou; Rui Zeng; Chuou Xu; Lili Liu; Lin Chen; Pei Kou; Guangchang Pei; Shoujun Bai; Yamin Zhang; Caixia Li; Song Rong; Min Han; Gang Xu
Journal:  J Mol Med (Berl)       Date:  2011-11-25       Impact factor: 4.599

Review 4.  Primers on molecular pathways--the NFAT transcription pathway in pancreatic cancer.

Authors:  Alexander König; Martin E Fernandez-Zapico; Volker Ellenrieder
Journal:  Pancreatology       Date:  2010-08-19       Impact factor: 3.996

Review 5.  Targeting tight junctions during epithelial to mesenchymal transition in human pancreatic cancer.

Authors:  Daisuke Kyuno; Hiroshi Yamaguchi; Tatsuya Ito; Tsuyoshi Kono; Yasutoshi Kimura; Masafumi Imamura; Takumi Konno; Koichi Hirata; Norimasa Sawada; Takashi Kojima
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

6.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.

Authors:  Nabeel Bardeesy; Kuang-Hung Cheng; Justin H Berger; Gerald C Chu; Jessica Pahler; Peter Olson; Aram F Hezel; James Horner; Gregory Y Lauwers; Douglas Hanahan; Ronald A DePinho
Journal:  Genes Dev       Date:  2006-11-15       Impact factor: 11.361

Review 7.  [Pathogenesis of the ductal pancreatic adenocarcinoma: implications for future therapies?].

Authors:  G Schneider; R M Schmid
Journal:  Internist (Berl)       Date:  2005-02       Impact factor: 0.743

8.  JDP2 inhibits the epithelial-to-mesenchymal transition in pancreatic cancer BxPC3 cells.

Authors:  Zhe Liu; Ruixia Du; Jin Long; Anbing Dong; Jianpeng Fan; Kejian Guo; Yuanhong Xu
Journal:  Tumour Biol       Date:  2012-04-27

9.  Hepatitis B virus X protein represses miRNA-148a to enhance tumorigenesis.

Authors:  Xiaojie Xu; Zhongyi Fan; Lei Kang; Juqiang Han; Chengying Jiang; Xiaofei Zheng; Ziman Zhu; Huabo Jiao; Jing Lin; Kai Jiang; Lihua Ding; Hao Zhang; Long Cheng; Hanjiang Fu; Yi Song; Ying Jiang; Jiahong Liu; Rongfu Wang; Nan Du; Qinong Ye
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

10.  Amplification of FGFR1 gene and expression of FGFR1 protein is found in different histological types of lung carcinoma.

Authors:  Vitor Sousa; Diana Reis; Maria Silva; Ana Maria Alarcão; Ana Filipa Ladeirinha; Maria João d'Aguiar; Teresa Ferreira; Sandra Caramujo-Balseiro; Lina Carvalho
Journal:  Virchows Arch       Date:  2016-05-19       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.